Arcutis Biotherapeutics (ARQT) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Arcutis Biotherapeutics, Inc. recently concluded a stock option exchange program, allowing employees and select consultants to swap stock options for new restricted stock units (RSUs) at varying exchange ratios based on the option exercise prices. With an overwhelming 98% participation rate, the program replaced options for about 5 million shares with approximately 2.1 million RSUs under the 2020 Equity Incentive Plan. The new RSUs, subject to a fresh vesting schedule, aim to realign employee interests with current market values following a dip in Arcutis’s stock prices.
For further insights into ARQT stock, check out TipRanks’ Stock Analysis page.